TNFSF13B Antibody (OASA01708)
- Known as:
- TNFSF13B Antibody (OASA01708)
- Catalog number:
- oasa01708
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- TNFSF13B Antibody (OASA01708)
Related genes to: TNFSF13B Antibody (OASA01708)
- Gene:
- TNFSF13B NIH gene
- Name:
- TNF superfamily member 13b
- Previous symbol:
- TNFSF20
- Synonyms:
- BAFF, THANK, BLYS, TALL-1, TALL1, CD257
- Chromosome:
- 13q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-19
- Date modifiied:
- 2018-11-22
Related products to: TNFSF13B Antibody (OASA01708)
Related articles to: TNFSF13B Antibody (OASA01708)
- Persistent minimal residual disease (MRD) significantly contributes to chemotherapy resistance and relapse in pediatric B-cell acute lymphoblastic leukemia (B-ALL), with conventional clinical risk factors insufficiently explaining the variability in patient prognoses. This study sought to explore potential mechanisms linked to sustained MRD by integrating analyses of clinical cohorts with single-cell transcriptomics, aiming to identify reliable biomarkers for risk stratification and targeted therapy. - Source: PubMed
Publication date: 2026/08/18
Zhang LinlinLiu XiaoyangChen FangXu GangFan Yang - Postoperative delirium (POD) and Alzheimer's disease (AD) are increasingly recognized as related neurocognitive conditions, but the aging-associated cell states that may connect them remain poorly defined. Here, we integrated two brain transcriptomic discovery datasets analyzed at single-cell/single-nucleus resolution, including a POD-related cohort (GSE291019) and an AD cohort (GSE129308), together with two independent peripheral-blood bulk transcriptomic datasets (GSE163943 and GSE63060), to identify aging-associated cellular programs and prioritize convergent molecular candidates. Across 184,168 high-quality cells, inhibitory neurons showed the most consistent aging-associated perturbation across the POD- and AD-related datasets. Re-clustering further identified three inhibitory-neuron subtypes, Inh_Neurons2, Inh_Neurons3, and Inh_Neurons5, with relatively high aging-related gene activity and preferential localization to later pseudotime states. Cross-platform integration of aging-associated inhibitory-neuron genes with a shared bulk DEG set identified four convergent candidates: RGL2, AKT1, SYK, and TNFSF13B. Among them, RGL2 emerged as the leading candidate, with the strongest downstream support concentrated in AD-related analyses. In two-sample Mendelian randomization, genetically predicted higher RGL2 expression was associated with increased AD risk, whereas the estimate for the delirium genome-wide association study proxy used for POD-related analyses was not significant. Pathway analyses further linked higher RGL2 expression to complement/coagulation and innate immune-inflammatory programs in AD-related analyses. These findings suggest a model in which POD and AD may partially intersect through aging-vulnerable inhibitory-neuron states and identify RGL2 as a prioritized candidate for downstream mechanistic investigation. - Source: PubMed
Publication date: 2026/08/29
Fan WeiHan ShuaiWang CunjingGao Ju - Epstein-Barr virus-associated gastric cancer (EBVaGC) is a distinct molecular subtype of gastric cancer, but reliable biomarkers linking EBV-related biology, prognosis, and microenvironmental remodeling remain limited. - Source: PubMed
Jin LufeiJiang ManPan YubinWang YanZhang LeiChen Wujie - Renal fibrosis represents the final common pathway of chronic kidney disease (CKD); however, both its definitive diagnostic biomarkers and the principal cellular mediators driving its progression remain incompletely characterized. - Source: PubMed
Publication date: 2026/08/24
Fazeli Seyed AmirhosseinJavanmard Amir-Reza - Multiple sclerosis (MS) is treated with branded or generic disease-modifying therapies (DMTs), with increasing concern for the composition and quality of off-patent products. Our objective was to evaluate differences in disease-specific biomarkers, a potential indicator of suboptimal therapeutic exposure, between individuals treated with branded and generic DMTs. We compared biomarker variability in MS individuals (n=1,124) treated with generic or brand-name fumarates (diroximel fumarate, dimethyl fumarate (DMF)), fingolimod, and teriflunomide. In the generic DMF group, higher coefficients of variation (COV) for CXCL9, CCL20, and TNFSF13B were observed, with a paradoxically lower variability for CXCL13. Higher COVs for CXCL9 were observed with generic fingolimod and for CXCL9 and CXCL13 with generic teriflunomide when compared to brand. Additionally, all generic DMTs demonstrated higher multi-variable variability index values across 18 proteins associated with MS disease activity. Greater biomarker variability with generic formulations may reflect differences in therapeutic exposure and less consistent disease control. - Source: PubMed
Publication date: 2026/08/23
Okuda Darin TAnderson Benjamin JTaylor Sophia MJones-McCreary Morgan CBurgess Katy WWright Crystal MSantoyo Jose RSguigna Peter VStüve OlafTran Diem HLight David YMoog Tatum MPunnen Tom G